MX2021003241A - Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. - Google Patents
Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.Info
- Publication number
- MX2021003241A MX2021003241A MX2021003241A MX2021003241A MX2021003241A MX 2021003241 A MX2021003241 A MX 2021003241A MX 2021003241 A MX2021003241 A MX 2021003241A MX 2021003241 A MX2021003241 A MX 2021003241A MX 2021003241 A MX2021003241 A MX 2021003241A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- intermediates
- manufacturing process
- crystalline form
- tosylate salt
- Prior art date
Links
- SDCVTUZMZOCTNV-UHFFFAOYSA-N 4-methylbenzenesulfonic acid 7H-pyrrolo[2,3-d]pyrimidine Chemical compound S(=O)(=O)(O)C1=CC=C(C)C=C1.N1C=NC=C2C1=NC=C2 SDCVTUZMZOCTNV-UHFFFAOYSA-N 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- CBRJPFGIXUFMTM-WDEREUQCSA-N 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one Chemical compound N1=CN=C(C2=C1NC=C2)N[C@@H]2CC[C@@H](N(C2)C(C=C)=O)C CBRJPFGIXUFMTM-WDEREUQCSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 150000003016 phosphoric acids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748628P | 2018-10-22 | 2018-10-22 | |
| PCT/IB2019/058940 WO2020084435A1 (en) | 2018-10-22 | 2019-10-21 | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003241A true MX2021003241A (es) | 2021-05-12 |
Family
ID=68343187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003241A MX2021003241A (es) | 2018-10-22 | 2019-10-21 | Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12116368B2 (enExample) |
| EP (1) | EP3870584A1 (enExample) |
| JP (1) | JP6944496B2 (enExample) |
| KR (1) | KR102629132B1 (enExample) |
| CN (1) | CN112888691B (enExample) |
| AR (1) | AR116797A1 (enExample) |
| AU (1) | AU2019363840B2 (enExample) |
| BR (1) | BR112021007568A2 (enExample) |
| CA (1) | CA3059000A1 (enExample) |
| IL (1) | IL282446B2 (enExample) |
| MX (1) | MX2021003241A (enExample) |
| SG (1) | SG11202103667QA (enExample) |
| TW (1) | TWI729530B (enExample) |
| WO (1) | WO2020084435A1 (enExample) |
| ZA (1) | ZA202101735B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2974946T3 (es) * | 2019-08-26 | 2024-07-02 | Chemwerth Inc | Compuestos (7H-pirrolo[2,3-d]pirimidin-4-il)amino sustituidos útiles como inhibidores de JAK1 |
| CN113121539A (zh) * | 2019-12-31 | 2021-07-16 | 江苏艾立康医药科技有限公司 | 一种pf06651600的制备方法 |
| BR112022010101A2 (pt) * | 2019-12-31 | 2022-09-06 | Pfizer R&D Uk Ltd | Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona |
| CN111620880B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600 dl-酒石酸盐，晶型及其制备方法 |
| CN111620879B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600马来酸盐，晶型及其制备方法 |
| CN111732591B (zh) * | 2020-06-15 | 2022-06-10 | 江苏艾立康医药科技有限公司 | Pf-06651600 l-酒石酸盐，晶型及其制备方法 |
| WO2022012587A1 (zh) * | 2020-07-14 | 2022-01-20 | 苏州晶云药物科技股份有限公司 | 丙烯酮类化合物的丙二酸盐晶型及其制备方法 |
| KR102473645B1 (ko) * | 2020-08-28 | 2022-12-05 | (주)부흥산업사 | (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법 |
| CN112877379B (zh) * | 2021-01-18 | 2023-09-01 | 华南理工大学 | 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法 |
| WO2025144783A1 (en) * | 2023-12-28 | 2025-07-03 | Aclaris Therapeutics, Inc. | Methods of synthesizing substituted pyrrolopyrimidine compounds |
| WO2025146702A1 (en) * | 2024-01-03 | 2025-07-10 | Msn Laboratories Private Limited, R&D Center | Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid |
| WO2025244944A1 (en) * | 2024-05-20 | 2025-11-27 | Opna Bio SA | Crystal forms of an agent |
| WO2025257773A1 (en) | 2024-06-11 | 2025-12-18 | Assia Chemical Industries Ltd. | Processes for the preparation of ritlecitinib and intermediates thereof |
| CN119060059B (zh) * | 2024-08-21 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种甲苯磺酸利特昔替尼的制备工艺 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999065908A1 (en) | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| ME02883B (me) | 2013-12-05 | 2018-04-20 | Pfizer | PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI |
| MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| CN105859721B (zh) * | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
-
2019
- 2019-10-16 JP JP2019189151A patent/JP6944496B2/ja active Active
- 2019-10-17 TW TW108137470A patent/TWI729530B/zh active
- 2019-10-17 CA CA3059000A patent/CA3059000A1/en active Pending
- 2019-10-21 AU AU2019363840A patent/AU2019363840B2/en active Active
- 2019-10-21 KR KR1020217015125A patent/KR102629132B1/ko active Active
- 2019-10-21 BR BR112021007568-2A patent/BR112021007568A2/pt unknown
- 2019-10-21 WO PCT/IB2019/058940 patent/WO2020084435A1/en not_active Ceased
- 2019-10-21 IL IL282446A patent/IL282446B2/en unknown
- 2019-10-21 MX MX2021003241A patent/MX2021003241A/es unknown
- 2019-10-21 EP EP19794259.2A patent/EP3870584A1/en active Pending
- 2019-10-21 CN CN201980069164.0A patent/CN112888691B/zh active Active
- 2019-10-21 SG SG11202103667QA patent/SG11202103667QA/en unknown
- 2019-10-21 US US17/286,018 patent/US12116368B2/en active Active
- 2019-10-22 AR ARP190103015A patent/AR116797A1/es unknown
-
2021
- 2021-03-15 ZA ZA2021/01735A patent/ZA202101735B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR116797A1 (es) | 2021-06-16 |
| JP6944496B2 (ja) | 2021-10-06 |
| TW202033525A (zh) | 2020-09-16 |
| KR102629132B1 (ko) | 2024-01-29 |
| TWI729530B (zh) | 2021-06-01 |
| WO2020084435A1 (en) | 2020-04-30 |
| ZA202101735B (en) | 2022-07-27 |
| IL282446B2 (en) | 2024-06-01 |
| KR20210080468A (ko) | 2021-06-30 |
| US20210387989A1 (en) | 2021-12-16 |
| SG11202103667QA (en) | 2021-05-28 |
| AU2019363840A1 (en) | 2021-04-01 |
| IL282446B1 (en) | 2024-02-01 |
| CA3059000A1 (en) | 2020-04-22 |
| US12116368B2 (en) | 2024-10-15 |
| CN112888691B (zh) | 2023-10-31 |
| AU2019363840B2 (en) | 2021-12-09 |
| EP3870584A1 (en) | 2021-09-01 |
| CN112888691A (zh) | 2021-06-01 |
| BR112021007568A2 (pt) | 2021-07-27 |
| IL282446A (en) | 2021-06-30 |
| JP2020066629A (ja) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003241A (es) | Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. | |
| MX2024005335A (es) | Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos. | |
| US8815853B2 (en) | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof | |
| MX2021012849A (es) | Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak. | |
| NZ737725A (en) | Crystalline forms of a bruton’s tyrosine kinase inhibitor | |
| IN2012DN02577A (enExample) | ||
| PH12013501627A1 (en) | Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivative | |
| MX2012009074A (es) | Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. | |
| MX2023006842A (es) | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. | |
| PT1299390E (pt) | Compostos de pirimidina e sua utilização na preparação de um triazolo-pirimidina-carbanucleósido | |
| MXPA05012025A (es) | Imidazo y tiazolopiridinas como inhibidores de cinasa jak3. | |
| MX2017016772A (es) | Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo. | |
| MX361992B (es) | Compuestos de pirrolopirimidina novedosos como inhibidores de proteínas quinasas. | |
| SG170783A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis | |
| MX385576B (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2 | |
| TW200614996A (en) | Antiviral compounds | |
| WO2016063294A3 (en) | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof | |
| EP3825317A3 (en) | Process for preparing btk inhibitors | |
| MX386181B (es) | Formas cristalinas de un inhibidor de quinasa janus | |
| AU2017319080A1 (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| MX2019007452A (es) | Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos. | |
| CL2020003227A1 (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak. | |
| MX2019005115A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| MY175052A (en) | Crystalline forms of (s) -4-amino-n- (1- (4 - chlorophenyl) - 3 - hydroxypropyl) -1- (7h - pyrrolo [2, 3-d] pyrimidi n-4-yl) piperidine-4-carboxamide | |
| EP3789374A3 (en) | Synthesis of 2'-fluoro-6'-methylene-carbocyclic adenosine (fmca) and 2'-fluoro-6'-methylene-carbocyclic guanosine (fmcg) |